By John Dudas
Patient licensing has widely been sensationalized as being a real threat to the innovation-promoting benefits of the patent system. However, as detailed in my last post, nothing could be further from the truth.
The August 2013 report from the US General Accountability Office (GAO) on US patent infringement litigation confirmed, both directly and indirectly, the view that there is no NPE patent litigation crisis and that, to the extent that there are problems with the patent system, they are linked primarily to patent quality, particularly in software-related patents, and to not the identity of the patent owner (e.g. NPE, PAE, PME, operating company).